More eyes will probe Kodak's deal to produce drug ingredients.
The Wall Street Journal reports the U.S. International Development Finance Corporation will review the $765 million loan announced back in July.
The Securities and Exchange Commission is already investigating allegations of insider trading related to the deal.
That includes CEO Jim Continenza, who apparently received Kodak stock options a day before the agreement was finalized.
Share prices spiked to over 60 dollars per share when the agreement was announced, but dropped sharply afterwards.
Right now, Kodak's share price sits at just over $6.00.